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INTRODUCTION
Most patients with neurofibromatosis type II (NF-II) will ev-
entually encounter bilateral deafness, creating an obstacle to 
social life. In patients with NF-II, sound amplification with he-
aring aids does not provide an effective solution, as speech dis-
crimination scores (SDSs) usually remain low in the presence 
of retrocochlear lesions. Certain NF-II patients with mild to 
moderate hearing loss might benefit slightly from the use of 
hearing aids; however, in most cases, their hearing loss is pro-
gressive and often inevitably exceeds a level that can be reha-
bilitated by hearing aids. 
In the past, no effective methods for rehabilitating patients 
with severe to profound hearing loss existed; consequently, 
lip-reading and sign language have been the only means of 
communication. In 1979, House and Hitselberger successfully 
performed a single-channel auditory brainstem implant (ABI) 
for the hearing rehabilitation of a patient with NF-II. Subse-
quently, the principles and concepts of treatment for patients 
with severe to profound hearing loss have changed. 
Advancements in electronic and medical devices have pro-
vided satisfactory treatment results in patients with severe to 
profound hearing loss. Otologists should be fully aware of the 
diverse indications and potential benefits of every possible 
hearing rehabilitation method in order to provide active sup-
port for patients with NF-II.
MECHANISMS OF HEARING LOSS  
IN NEUROFIBROMATOSIS TYPE II
NF-II is an autosomal dominant neoplastic syndrome. It has 
an incidence of 1 in 25000 people and a penetrance of nearly 
100% at 60 years of age.1 Clinical manifestations include cen-
tral and peripheral nervous system tumors, and the hallmark 
of NF-II is the development of bilateral vestibular schwanno-
mas (VSs), which present in 90% to 95% of NF-II patients.2 
Though VSs are benign tumors, they cause significant hearing 
loss, with binaural hearing loss occurring in nearly all NF-II 
patients. However, the mechanisms of hearing loss in NF-II are 
not truly understood. 
The most frequent hypothesis regarding the source of hear-
ing loss in NF-II is that it is caused by direct compression of the 
cochlear nerve. Previous studies have reported that the pres-
ence of hearing loss is correlated with larger tumor volumes.3 
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However, this hypothesis cannot explain hearing loss when 
tumors are small, progressive hearing loss in the presence of 
non-growing tumors, or unpredictable onset of hearing loss.4,5 
In 2012, Roosli, et al.6 reviewed the histopathology of cochle-
ae in patients with VSs and observed loss of inner and outer 
hair cells, atrophy of the stria vascularis, loss of cochlear neu-
rons, and the presence of endolymphatic hydrops. The non-
tumorous cochleae did not present with such changes. These 
structural changes were not correlated with tumor size or dis-
tance from the cochlea.6 These findings indicate that hearing 
loss in VSs is more likely due to end organ failure than proxi-
mal cochlear nerve functions. It was recently reported that el-
evated levels of intralabyrinthine protein as observed via fluid 
attenuated inversion recovery magnetic resonance imaging 
(FLAIR MRI) is closely associated with hearing loss in NF-II.3 
Intralabyrinthine protein elevation is caused by cochlear ap-
erture obstruction or destruction by VSs and explains the end 
organ failure in NF-II. It was also demonstrated that increases 
in intralabyrinthine protein obtained from perilymph aspira-
tion could accurately identify the presence of VSs.7 
HEARING AIDS 
The pattern of hearing loss is unpredictable in NF-II. Sudden, 
relapsing, or progressive hearing loss may occur regardless of 
tumor size or time from initial diagnosis. However, the natural 
history of hearing loss in NF-II has previously been studied.4 
In this study, 108 ears were examined; the pure-tone average 
(PTA) at baseline was 22.2±21.8 dB with a mean SDS of 93.9± 
13.1%. Without treatment, the follow-up PTA at 2 years de-
creased to 37.0±31.4 dB, and SDS also dropped to 83.9±28.4%. 
NF-II is likely to be diagnosed before any loss of hearing, indi-
cating that in most cases, the baseline hearing is normal. This 
decrease is faster and more severe than that of general age-re-
lated hearing loss,8 and of note, a decrease in SDS severely re-
duces the effectiveness of hearing aids. While hearing aids 
can be helpful for any patient with hearing loss, those with mo-
derate levels of loss receive the most potential benefit. Severe 
or profound loss can limit the usefulness of even the most pow-
erful hearing aids. In many cases of profound hearing loss, a 
hearing aid can only provide environmental awareness or a de-
gree of rudimentary perception of speech.9 
Contralateral routing of signals (CROS) hearing aids have 
been introduced to provide audiologic benefits by routing the 
sound from the hearing-impaired side to the intact ear. Use of 
CROS hearing aids is the easiest method for rehabilitation in 
patients with asymmetric hearing loss without surgery; how-
ever, there are several limitations, including poor cosmetics 
due to the use of two hearing aids with a connection wire, dis-
comfort from the occlusion of the better ear, and most of all, 
degradation of speech intelligibility in certain demanding sit-
uations10 and significant deficit in noisy environments.11 De-
spite its convenience and simplicity, cosmetic inferiority and 
discomfort from the occlusion effect in the normal ear has pre-
cluded the widespread use of CROS as a conventional type of 
hearing aid.
BONE-CONDUCTION HEARING IMPLANT
For patients with single-sided deafness, occurring either sp-
ontaneously or after tumor removal, a bone-conduction hear-
ing implant (BCHI) can be a good hearing rehabilitation op-
tion. In this option, the speech processor receives the auditory 
signal and transforms it to a vibration, after which the BCHI 
transmits the vibration to both the ipsilateral and contralateral 
cochleae as it passes through the skin and skull. Conductive 
hearing loss, mixed hearing loss, and single-sided deafness 
are all good candidates for BCHI. In cases of patients with sin-
gle-sided deafness, the vibration generated from the deaf side 
is transferred to the contralateral normal cochlea, where it can 
be recognized. However, BCHI is not as applicable to binaural 
hearing, as it does not offer many of the advantages of binaural 
hearing: summation effects, binaural squelch, and sound lo-
calization cannot be attained (Fig. 1). Despite these limitations, 
patients’ satisfaction with BCHI is usually quite high.12,13 
From its first introduction in 1976,14 BCHIs have developed 
at a remarkable pace, and various products have been com-
mercialized or are in clinical trials. BCHIs can be classified ac-
cording to transmit system: one is a direct-drive system that 
transmits the vibration through the skull, and the other is a skin-
drive system that transmits the vibration through the skin (Fig. 2). 
Examples of direct-drive systems include Ponto® (Oticon Me-
dical, Smørum, Denmark), Baha® BP100 (Cochlear Bone An-
Fig. 1. Mechanisms of a bone-conduction hearing implant. Vibrations gen-
erated from the device are transferred to the contralateral cochlea and 
recognized on the contralateral side.
Cochlea
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chored Solutions AB, Molnlycke, Sweden), and BonebridgeTM 
(MED-EL, Innsbruck, Austria). The Ponto® and Baha® BP100 
systems use screws to attach the speech processor to the skull, 
so that the vibrations generated from the device are directly 
transmitted to the skull. They are known to achieve a sufficient 
hearing gain, as the vibration directly transmits via the screw, 
and a degree of binaural squelch effect has also been report-
ed.15 Despite the above-mentioned benefits, recipients often 
suffer from various skin problems and loosening of the screws 
due to their fixation methods.16 To overcome these limitations, 
active transcutaneous devices were introduced. In the case of 
the BonebridgeTM system, active BCHIs are implanted into the 
temporal bone and vibrate within the temporal bone. Speech 
processors are attached to the scalp through magnets. This 
promotes sufficient hearing gain and is not associated with 
any skin problems. However, larger internal devices are re-
quired, which has made it difficult to perform such implanta-
tions in children or in patients who have undergone previous 
mastoidectomy. Various methods are followed to overcome 
these limitations, such as the use of a lift system or the retrosi-
gmoid approach (RSA).17 
A skin-drive system generates the vibration outside of the 
skull. The vibration must pass through the skin to reach the 
skull. Softband Baha® (Cochlear Bone Anchored Solutions AB, 
Molnlycke, Sweden), Sophono® (Medtronic, Louisville, CO, 
USA), and Baha® Attract (Cochlear Bone Anchored Solutions 
AB, Molnlycke, Sweden) use this system. Softband Baha® uses 
elastic headbands around the head, instead of screws, to fix the 
device to the skull. It can be used with children who are too young 
to undergo implant surgery.18 In addition, it is quite effective at 
simulating and predicting the outcomes of BCHIs and can thus 
be used with patients who are planning to undergo BCHI sur-
geries.19 However, for secure fixation, the pressure that is requ-
ired may cause deformations of the skin and subcutaneous 
tissues, and tension headaches. This problem can be solved by 
using magnets, which is how the speech processors of Sopho-
no® and Baha® Attract are attached to the scalp. However, thick 
skin could weaken the magnetic forces and reduce the fixation; 
thus, the thickness of skin should be less than 5 mm.20 A skin-
drive system tends to have less hearing gain than a direct-drive 
system due to the attenuation of the mechanical energy as it pass-
es through skin;21 however, theoretically it can be overcome by 
fixing the speech processor in the proper location with ade-
quate pressure.22 
As all BCHIs contain permanent magnets, MRI compatibil-
ity is a challenging concern. Computed tomography (CT) sh-
ould be used as a first choice for the safety of both patients and 
devices; however, certain clinical conditions require an MRI 
scan in order to obtain proper image information. In cases of 
NF-II, regular MR imaging is required. BonebridgeTM and So-
phono® are certified to be conditionally safe up to 1.5 and 3 
Tesla,23 respectively, although there will be an image artifact in 
the region near the implant. Manufacturers have specified the 
size of the corresponding MRI artifact, specifically, a sphere of 
15 cm in diameter for BonebridgeTM, a distance of 5–10 cm 
from the Sophono® implant, and a distance of 11.5 cm from the 
center of the Baha® Attract implant.24,25 Steinmetz, et al.26 also 
reported a 29-year-old patient with VS who was scanned with 
a BonebridgeTM implant on the contralateral side; due to the 
image artifact, the tumor was concealed. If an MRI absolutely 
needs to be performed with a focus on structures in the skull 
near the implant, the implant must be explanted to eliminate ar-
Fig. 2. Categorization of bone-conduction hearing implants. (A) Ponto®. (B) Baha® BP100. (C) BonebridgeTM. (D) Softband Baha®. (E) Baha® Attract. (F) So-
phono®. Photos provided courtesy of Oticon Medical (A), Cochlear Bone Anchored Solutions AB (B, D, and E), MED-EL (C), and Medtronic (F).
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tifacts. Therefore, in patients with NF-II, it is important to select 
the proper implant for such an event. 
COCHLEAR IMPLANT
In the early days of their use, patients with ABIs were only able 
to recognize environmental sounds or to detect sounds with a 
further reliance on lip-reading, and they were not capable of 
discriminating speech sounds.27 For better hearing rehabilita-
tion, a cochlear implant (CI) is applied to patients with NF-II. 
CIs offer many advantages over ABIs, and the most important 
benefit is that CIs can provide better speech understanding. 
As intracochlear electrode placement permits reliable tonotop-
ic stimulation, better auditory performance is generally ex-
pected.28 A CI can be attempted either with the tumor remain-
ing in place or after the tumor has been removed. 
Two decades ago, the first CI was performed simultaneous-
ly with the removal of a tumor in a patient with NF-II.29 CI was 
also attempted on patients who were non-surgically treated, 
such as those who underwent stereotactic radiotherapy [or a 
gamma knife surgery (GS)] or refused to undergo surgery. GS 
is an alternative to surgery for tumor control and has been pro-
posed to allow hearing preservation, though it is not without 
risks. Prasad, et al.30 reported the outcomes of 200 cases of VSs 
that were treated with GS, and 25% demonstrated either an 
increase or no changes of volume, while hearing deterioration 
was found in 60% of the patients over a 6-year period. Out-
comes for CI after GS for VS are varied in that some were able 
to achieve good post-implantation speech perception, while 
others were only capable of detecting environmental sounds.31 
However, regardless of the variable outcomes, the problem is 
that tumors can grow at any time without complete tumor re-
moval, and larger tumors are correlated with hearing loss.3 
Additionally, the function of CI after GS for VS is likely to de-
crease over time, and malignant transformation is also a con-
cern. There have been reported cases of malignant transfor-
mation of tumors in NF-II following GS, and reports suggest 
that up to 50% of all malignant transformations occur in NF-II 
patients.32 It is important to remember that regular follow-up 
via MRI is critical when patients are non-surgically treated. If 
such imaging is obtained with the magnetic device implanted, 
many adverse effects could occur. MRI performed on patients 
with an implanted magnetic device could potentially result in 
a migration of the device. Demagnetization and malfunction 
of the devices could also occur, and the heating of such internal 
devices could damage the surrounding tissues. These effects 
can be avoided by removing the magnets before performing 
MRI scans or by using low-Tesla (T) MRI. Current US Food 
and Drug Administration (FDA) guidelines have approved the 
use of 0.2 to 1.5 T with the magnet in place.33 Generally, MRI 
in patients with a magnetic device is reported to be safe with 
elastic head bands placed around their heads.34 Furthermore, 
heat from the CI during 1.5-T MRI is reported to be lower than 
0.1°C;34 hence, usage of 1.5-T MRI with the magnetic device is 
relatively safe. However, image quality obtained from the MRI 
scan is another issue. Ipsilateral soft tissues within 7 to 8 cm 
from the magnet are poorly visualized, while the contralateral 
side image has no distortion.35 Several otologists recommend 
simultaneous high-resolution computed tomography (HRCT) 
imaging and a comparison of the images for better expression. 
If CI is to be performed simultaneously with tumor removal, 
it is necessary to preserve the cochlear nerve while removing 
the tumor. VSs mostly originate from vestibular nerves; there-
fore, preserving the cochlear nerve while removing the tumor 
is possible in certain cases.36 Sporadic VSs tend to grow and 
only compress the nearby cochlear nerve. However, VSs in pa-
tients with NF-II directly invade into the cochlear nerve37 and 
are quite adherent to the cochlear nerve, making safe dissec-
tion of the cochlear nerve from the tumor difficult.29 Although 
anatomically well-separated, histological injuries such as mi-
nor bleeding or an axonal injury might decline the function of 
the cochlear nerve.38 However, though an injured cochlear 
nerve cannot function with the auditory signal, the nerve can 
function with a direct electrical signal under the conditions of 
the CI. Response to an electrical signal can be evaluated by 
stimulating the cochlear promontory with an electrode during 
the operation. 
Various approach techniques can be applied; however, a 
translabyrinthine approach (TLA) is known to be the best ap-
proach for accomplishing both complete tumor removal and 
successful CI. TLA, which provides the otologist with a famil-
iar surgical view, offers early identification of the cochlear nerve 
in the auditory canal during the surgery and eliminates any 
need for cerebellar retraction.39 Cole, et al.40 compared the 
RSA with TLA for VS resection and observed that TLA was as-
sociated with a lower risk of cochlear nerve injury, which is 
essential for performing CI, dysphagia, and dysrhythmia. 
There are many reports of performing CIs after tumor remov-
al in either sporadic or NF-II-associated VSs.31,41-44 Generally, 
outcomes for sound field and speech perception in post-lingual 
CI patients and in patients with tumors have been similar, and 
half of the patients with tumors were able to communicate on 
telephones.45 It is not certain what the appropriate time inter-
val is between implantation and tumor removal. Theoretically, 
simultaneous implantation would reduce the possibility of 
failure, as the chance of fibrosis or ossification of the cochlea 
could be avoided. Furthermore, distortion of the anatomy due 
to tumor removal can be minimized if the implantation is per-
formed simultaneously. The time required for fibrosis or ossi-
fication of the cochlea to occur is unknown; however, there 
have been reports of CI failure occurring due to cochlear ossi-
fication when performed 1 year after removing a tumor via 
TLA.43 On the other hand, there is also a report of a successful 
implantation being performed 3 months after the tumor re-
moval, via the same approach.42 
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AUDITORY BRAINSTEM IMPLANT
After the first successful implantation in 1979, ABIs were origi-
nally the only way to restore hearing in patients with NF-II. Ini-
tially, ABIs were developed for patients who could not benefit 
from a CI, i.e., patients with non-functioning cochlear nerves. 
Patients with NF-II are typical candidates; however, the indi-
cations of ABI are becoming wider, such that patients with a co-
chlear anomaly or a cochlear ossification following meningitis 
are now also good candidates.46
The operation principle of an ABI is similar to that of a CI. In 
cases of CIs, the external auditory processor receives the audi-
tory signal and transforms it into an electrical signal. This sig-
nal is then transmitted to the electrode that was inserted into 
the cochlea, and the stimulation is delivered to the auditory 
nerve. Finally, the auditory signal is recognized in the brain. 
In cases of ABIs, the electrode is inserted in the cochlear nu-
cleus, which is located at the brainstem, proximal to the audi-
tory nerve. The transformed signal is then transmitted to the 
electrode, and the brain recognizes the signal (Fig. 3).
The cochlear nucleus is located on the dorsal lateral side of 
the lateral recess of brainstem and can be accessed via the Fo-
ramen of Luschka. For successful implantation, inserting the 
electrode into the exact location of the cochlear nucleus is key 
to the procedure. However, detecting the exact location is dif-
ficult, as these structures are covered with flocculus and are 
not easily observed in a natural state due to the occurrence of 
anatomical distortions from either the tumor itself or the op-
eration. TLA provides the otologist with a familiar and direct 
surgical view, providing a solution to this anatomical prob-
lem. Furthermore, TLA is free from cerebellar retraction and 
is advantageous when performing ABI. A total of 90% to 95% 
Fig. 3. Concurrent tumor removal and auditory brainstem implant via the translabyrinthine approach. (A) Implantable internal device. (B) Diagram of auditory 
brainstem implant via translabyrinthine approach. The tumor, which originated from the cochleovestibular nerve, was resected with the nerve. A flat elec-
trode was inserted, which stimulated the dorsal cochlear nucleus. Photos provided courtesy of Cochlear Headquarters (A). The figure was created by 
Dong-Su Jang, medical illustrator (B).
A B
Fig. 4. Comparison of the retrosigmoid approach and the translabyrinthine approach for tumor removal. (A) Severe cerebellar retraction is needed to ex-
pose the tumor; however, tumors in the internal auditory canal are not readily removable via the retrosigmoid approach. (B) In the translabyrinthine ap-
proach, tumors in the internal auditory canal are well exposed without cerebellar retraction. Arrows indicate the direction of visual field.
A B
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of cases of NF-II have bilateral VSs.2 If a contralateral VS is too 
large, cerebellar retraction is hardly feasible; thus, RSA would 
not be able to provide the proper surgical views. Moreover, 
VSs in NF-II are likely to grow into the internal auditory canal,47 
preventing complete tumor resection via RSA (Fig. 4). For these 
reasons, TLA is recommended by experienced surgeons.48 In-
tra-operative monitoring is also strongly recommended for bet-
ter detection of the exact implant location.49 
ABIs provide effective hearing rehabilitation for patients who 
cannot benefit from CI. Since the first ABI in 1979, House Ear 
Institute (Los Angeles, CA, USA) surgeons have performed 
more than 230 ABIs. In their patient series, 85% were able to 
detect the auditory signal, and 93% showed great improvement 
in understanding sentences with the assistance of lip-reading.27 
In 2002, two implantees were reported to have the ability to 
communicate on the phone.50 Vincenti, et al.43 compared the 
outcomes of hearing rehabilitation in patients with NF-II who 
underwent tumor removal and received either a CI or ABI at a 
single institute. In closed-set conditions, patients with a CI 
showed outstanding results compared to patients with an ABI. 
However, in open-set conditions, the two groups did not show 
significant differences. CIs in cases of NF-II need to preserve 
the cochlear nerve while completely removing the tumor, which 
is a difficult task. Remaining tumor tissue lowers the CI func-
tion and makes it difficult to follow-up via MRI. With ABIs, on 
the other hand, it is possible to perform the surgery without 
preserving the cochlear nerve, making it easier to completely 
remove the tumor and follow-up via MRI.
CONCLUSION
VSs, especially in cases of NF-II, were once considered to be a 
life-threatening disease. However, with early diagnosis, treat-
ment with a multidisciplinary approach, and advancements 
in electronic and medical devices, not only have survival rates 
improved but the quality of life has also substantially been en-
hanced with options for successful hearing rehabilitation. 
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